{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.540","value":"0.626"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"}],"units":"Participants"}],"title":"C1D1, Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.881","value":"1.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"}],"units":"Participants"}],"title":"C1D1, 4 hours Post-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.745","value":"0.681"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"}],"units":"Participants"}],"title":"C4D1, Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.905","value":"1.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"}],"units":"Participants"}],"title":"C4D1, 4 hours Post-Dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants were initially placed on a venetoclax ramp-up period of 5 weeks and received an initial dose of 20 mg via tablet orally once daily (QD) for initial 1 to 7 days, then venetoclax dose was incremented weekly up to a maximum dose of 400 mg, orally, QD. Participants continued receiving venetoclax at a dose of 400 mg, orally, QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to PD or 2 years, whichever occurred first, as directed by the investigator, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG000","title":"Venetoclax + Rituximab Main Study"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) evaluable population included all participants in the 'Venetoclax + Rituximab' arm who received at least one dose of venetoclax with at least one post-dose PK concentration result available. Here 'Number Analyzed' signifies the number of participants evaluable at specified time point.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hour, anytime before venetoclax administration) and 4 hours post-dose on D1 of Cycles 1 and 4; Cycle length = 28 days","title":"Plasma Venetoclax Concentrations","type":"SECONDARY","unitOfMeasure":"micrograms per milliliter (mcg/mL)"}